These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38598571)

  • 1. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.
    de Boniface J; Filtenborg Tvedskov T; Rydén L; Szulkin R; Reimer T; Kühn T; Kontos M; Gentilini OD; Olofsson Bagge R; Sund M; Lundstedt D; Appelgren M; Ahlgren J; Norenstedt S; Celebioglu F; Sackey H; Scheel Andersen I; Hoyer U; Nyman PF; Vikhe Patil E; Wieslander E; Dahl Nissen H; Alkner S; Andersson Y; Offersen BV; Bergkvist L; Frisell J; Christiansen P; ;
    N Engl J Med; 2024 Apr; 390(13):1163-1175. PubMed ID: 38598571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
    JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
    Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
    Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial.
    Andersson Y; Bergkvist L; Frisell J; de Boniface J
    Br J Surg; 2021 Sep; 108(9):1105-1111. PubMed ID: 34010418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.
    Donker M; van Tienhoven G; Straver ME; Meijnen P; van de Velde CJ; Mansel RE; Cataliotti L; Westenberg AH; Klinkenbijl JH; Orzalesi L; Bouma WH; van der Mijle HC; Nieuwenhuijzen GA; Veltkamp SC; Slaets L; Duez NJ; de Graaf PW; van Dalen T; Marinelli A; Rijna H; Snoj M; Bundred NJ; Merkus JW; Belkacemi Y; Petignat P; Schinagl DA; Coens C; Messina CG; Bogaerts J; Rutgers EJ
    Lancet Oncol; 2014 Nov; 15(12):1303-10. PubMed ID: 25439688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.
    Galimberti V; Cole BF; Viale G; Veronesi P; Vicini E; Intra M; Mazzarol G; Massarut S; Zgajnar J; Taffurelli M; Littlejohn D; Knauer M; Tondini C; Di Leo A; Colleoni M; Regan MM; Coates AS; Gelber RD; Goldhirsch A;
    Lancet Oncol; 2018 Oct; 19(10):1385-1393. PubMed ID: 30196031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer.
    de Boniface J; Ahlgren J; Andersson Y; Bergkvist L; Frisell J; Lundstedt D; Olofsson Bagge R; Rydén L; Sund M;
    Breast Cancer Res Treat; 2020 Feb; 180(1):167-176. PubMed ID: 31989379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
    Giuliano AE; Hunt KK; Ballman KV; Beitsch PD; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; McCall LM; Morrow M
    JAMA; 2011 Feb; 305(6):569-75. PubMed ID: 21304082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial.
    Appelgren M; Sackey H; Wengström Y; Johansson K; Ahlgren J; Andersson Y; Bergkvist L; Frisell J; Lundstedt D; Rydén L; Sund M; Alkner S; Vrou Offersen B; Filtenborg Tvedskov T; Christiansen P; de Boniface J;
    Breast; 2022 Jun; 63():16-23. PubMed ID: 35279508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolution of the sentinel node procedure in the treatment of breast cancer.
    Tvedskov TF
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial.
    de Boniface J; Frisell J; Andersson Y; Bergkvist L; Ahlgren J; Rydén L; Olofsson Bagge R; Sund M; Johansson H; Lundstedt D;
    BMC Cancer; 2017 May; 17(1):379. PubMed ID: 28549453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.
    Galimberti V; Cole BF; Zurrida S; Viale G; Luini A; Veronesi P; Baratella P; Chifu C; Sargenti M; Intra M; Gentilini O; Mastropasqua MG; Mazzarol G; Massarut S; Garbay JR; Zgajnar J; Galatius H; Recalcati A; Littlejohn D; Bamert M; Colleoni M; Price KN; Regan MM; Goldhirsch A; Coates AS; Gelber RD; Veronesi U;
    Lancet Oncol; 2013 Apr; 14(4):297-305. PubMed ID: 23491275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of occult metastases on survival in node-negative breast cancer.
    Weaver DL; Ashikaga T; Krag DN; Skelly JM; Anderson SJ; Harlow SP; Julian TB; Mamounas EP; Wolmark N
    N Engl J Med; 2011 Feb; 364(5):412-21. PubMed ID: 21247310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing Early-Stage Breast Cancer Patients with Sentinel Lymph Node Metastasis with and without Completion Axillary Lymph Node Dissection: A Systematic Review and Meta-Analysis.
    Heiranizadeh N; Rafiei Shahamabadi M; Dehghan HR; Jafari-Nedooshan J; Kargar S; Zare M; Amooei A; Shiryazdi SM; Broomand MA; Moravej MT; Sadri Z
    Asian Pac J Cancer Prev; 2022 Aug; 23(8):2561-2571. PubMed ID: 36037108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.
    Faries MB; Thompson JF; Cochran AJ; Andtbacka RH; Mozzillo N; Zager JS; Jahkola T; Bowles TL; Testori A; Beitsch PD; Hoekstra HJ; Moncrieff M; Ingvar C; Wouters MWJM; Sabel MS; Levine EA; Agnese D; Henderson M; Dummer R; Rossi CR; Neves RI; Trocha SD; Wright F; Byrd DR; Matter M; Hsueh E; MacKenzie-Ross A; Johnson DB; Terheyden P; Berger AC; Huston TL; Wayne JD; Smithers BM; Neuman HB; Schneebaum S; Gershenwald JE; Ariyan CE; Desai DC; Jacobs L; McMasters KM; Gesierich A; Hersey P; Bines SD; Kane JM; Barth RJ; McKinnon G; Farma JM; Schultz E; Vidal-Sicart S; Hoefer RA; Lewis JM; Scheri R; Kelley MC; Nieweg OE; Noyes RD; Hoon DSB; Wang HJ; Elashoff DA; Elashoff RM
    N Engl J Med; 2017 Jun; 376(23):2211-2222. PubMed ID: 28591523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalizing Locoregional Therapy in Patients With Breast Cancer in 2024: Tailoring Axillary Surgery, Escalating Lymphatic Surgery, and Implementing Evidence-Based Hypofractionated Radiotherapy.
    Weber WP; Hanson SE; Wong DE; Heidinger M; Montagna G; Cafferty FH; Kirby AM; Coles CE
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438776. PubMed ID: 38815195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.
    Simons JM; van Nijnatten TJA; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef C; Sars PRA; Heijmans HJ; van Haaren ERM; Vles WJ; Contant CME; Menke-Pluijmers MBE; Smit LHM; Kelder W; Boskamp M; Koppert LB; Luiten EJT; Smidt ML
    JAMA Surg; 2022 Nov; 157(11):991-999. PubMed ID: 36069889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
    Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
    Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07).
    van Roozendaal LM; de Wilt JH; van Dalen T; van der Hage JA; Strobbe LJ; Boersma LJ; Linn SC; Lobbes MB; Poortmans PM; Tjan-Heijnen VC; Van de Vijver KK; de Vries J; Westenberg AH; Kessels AG; Smidt ML
    BMC Cancer; 2015 Sep; 15():610. PubMed ID: 26335105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.